Clinical Trials

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Hepatocellular, Neoplasms

NCT05919264 2026-04-09

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT03505320 2026-04-03

ILUSTRO

Phase 2 Active not recruiting

143 enrolled

Neoplasms, Stomach Neoplasms

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT07276373 2026-04-03

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

50 enrolled

Phase 1 Not yet recruiting

Neoplasms

NCT07476326 2026-04-03

Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma

120 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Neoplasms

NCT04336241 2026-02-27

Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors

BreastDermatologicGastrointestinalThoracic

36 enrolled

Uveal Melanoma, Breast Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasms

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

281 enrolled 44 charts

Phase 1/2 Active not recruiting

Melanoma, Neoplasms

NCT04078295 2026-02-10

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

125 enrolled

Neoplasms

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

57 enrolled

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT06764771 2025-12-17

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

GastrointestinalGenitourinaryThoracic

437 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

DermatologicGastrointestinalThoracic

463 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

68 enrolled 27 charts

Phase 3 Active not recruiting

Neoplasms

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

237 enrolled

Phase 3 Active not recruiting

Neoplasms

NCT03522246 2025-06-24

ATHENA

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT05180799 2025-06-15

A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Phase 1/2 Active not recruiting

320 enrolled

Phase 1/2 Active not recruiting

Melanoma, Neoplasm Metastasis, Neoplasms

NCT05888831 2025-06-11

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

100 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

39 enrolled

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

35 enrolled

Neoplasms

NCT03447470 2025-01-29

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

46 enrolled 29 charts

Biliary Tract Neoplasms, Neoplasms, Thymus Neoplasms

NCT04350463 2025-01-22

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Phase 2 Completed

92 enrolled 25 charts

Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT03667716 2025-01-17

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

BreastGastrointestinalGynecologicThoracic

121 enrolled

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04109066 2025-01-08

CheckMate 7FL

Phase 3 Completed

521 enrolled 17 charts

Breast

Breast Neoplasms, Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03565445 2024-11-01

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & Neck

190 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT06274437 2024-08-07

A Study of BND-35 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

280 enrolled

Neoplasms

NCT02848443 2024-07-25

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

78 enrolled

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT04319224 2024-05-30

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Phase 1/2 Terminated

4 enrolled 10 charts

Neoplasms

NCT02705105 2024-04-25

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

114 enrolled 19 charts

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT04200963 2024-03-15

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

78 enrolled

Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

NCT04892043 2024-02-23

Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1 Terminated

5 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03123783 2023-12-26

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

140 enrolled 16 charts

DermatologicThoracic

Lung Neoplasms, Melanoma, Neoplasms

NCT02467361 2023-11-14

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

104 enrolled

Neoplasms

NCT02483247 2023-11-14

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

165 enrolled

Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

7 enrolled

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT02439450 2023-09-21

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

121 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02904226 2023-07-03

ICONIC

242 enrolled 29 charts

Neoplasms

NCT04084951 2023-04-14

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

30 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT03396211 2023-04-07

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

30 enrolled

Neoplasm Metastasis, Neoplasms

NCT04112498 2023-04-06

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

24 enrolled

CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Phase 1/2 Terminated

15 enrolled 14 charts

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Phase 1/2 Terminated

80 enrolled 33 charts

DermatologicGastrointestinalGenitourinaryThoracic

Neoplasms

NCT04311710 2023-02-24

CheckMate 76U

Phase 1 Terminated

21 enrolled

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

337 enrolled 42 charts